Media stories about Aratana Therapeutics (NASDAQ:PETX) have trended positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a news impact score of 0.29 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.8832671499903 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern’s rankings:
- Aratana Therapeutics (PETX) Confirms Receipt of Board Nominations from Engaged Capital (streetinsider.com)
- 13D Filing: Engaged Capital and Aratana Therapeutics Inc. (PETX) (feedproxy.google.com)
- -$0.18 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter (americanbankingnews.com)
- Aratana Therapeutics (PETX) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Aratana Therapeutics (PETX) and The Competition Financial Contrast (americanbankingnews.com)
Aratana Therapeutics stock opened at $5.09 on Friday. The company has a market capitalization of $212.76, a PE ratio of -5.25 and a beta of 2.91. Aratana Therapeutics has a 1 year low of $3.67 and a 1 year high of $7.67. The company has a current ratio of 2.40, a quick ratio of 2.02 and a debt-to-equity ratio of 0.24.
PETX has been the topic of a number of analyst reports. HC Wainwright set a $10.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, January 16th. CL King initiated coverage on shares of Aratana Therapeutics in a research note on Wednesday, December 27th. They set a “neutral” rating on the stock. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Stifel Nicolaus reaffirmed a “hold” rating and set a $6.00 target price on shares of Aratana Therapeutics in a research note on Monday, December 18th. Finally, ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Aratana Therapeutics currently has a consensus rating of “Hold” and an average target price of $8.68.
In other news, CEO Peter Steven St sold 19,367 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total value of $92,380.59. Following the sale, the chief executive officer now directly owns 672,259 shares of the company’s stock, valued at approximately $3,206,675.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Craig A. Tooman sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $5.27, for a total transaction of $158,100.00. Following the completion of the sale, the insider now directly owns 75,024 shares in the company, valued at $395,376.48. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Favorable Media Coverage Somewhat Unlikely to Impact Aratana Therapeutics (NASDAQ:PETX) Share Price” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/favorable-news-coverage-somewhat-unlikely-to-impact-aratana-therapeutics-petx-share-price/2029656.html.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.